S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Nuvalent Stock Price, News & Analysis (NASDAQ:NUVL)

$67.16
+0.96 (+1.45%)
(As of 12/4/2023 ET)
Compare
Today's Range
$65.98
$68.24
50-Day Range
$42.08
$67.16
52-Week Range
$23.09
$68.24
Volume
454,732 shs
Average Volume
390,372 shs
Market Capitalization
$4.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.86

Nuvalent MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
9.4% Downside
$60.86 Price Target
Short Interest
Bearish
21.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.04mentions of Nuvalent in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$6.04 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.16) to ($2.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.04 out of 5 stars

Medical Sector

941st out of 952 stocks

Pharmaceutical Preparations Industry

429th out of 434 stocks


NUVL stock logo

About Nuvalent Stock (NASDAQ:NUVL)

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL Stock Price History

NUVL Stock News Headlines

Nuvalent, Inc. (NASDAQ:NUVL) Director Sells $566,293.50 in Stock
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Nuvalent Q3 Loss Widens
Nuvalent Inc.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Nuvalent Inc Class A NUVL
Nuvalent (NUVL) Gets a Buy from Stifel Nicolaus
Why Nuvalent Stock Tanked on Tuesday
Where Nuvalent Stands With Analysts
See More Headlines
Receive NUVL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NUVL
Fax
N/A
Employees
89
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.86
High Stock Price Target
$79.00
Low Stock Price Target
$42.00
Potential Upside/Downside
-9.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-81,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.59 per share

Miscellaneous

Free Float
53,380,000
Market Cap
$4.21 billion
Optionable
Not Optionable
Beta
1.39
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. James R. Porter Ph.D. (Age 47)
    CEO, President & Director
    Comp: $998.02k
  • Prof. Matthew D. Shair Ph.D. (Age 54)
    Founder, Head of Scientific Advisory Board & Director
    Comp: $235k
  • Ms. Alex Balcom CPA (Age 38)
    M.B.A., CFO & Treasurer
    Comp: $654.22k
  • Dr. Christopher D. Turner M.D. (Age 54)
    Chief Medical Officer
    Comp: $714.26k
  • Dr. Benjamin Lane
    Senior Vice President of Technical Operations
  • Ms. Deborah Ann Miller J.D.Ms. Deborah Ann Miller J.D. (Age 47)
    Ph.D., Chief Legal Officer & Secretary
    Comp: $595.96k
  • Mr. Matthew Metivier
    Vice President of Human Resources
  • Ms. Darlene NociMs. Darlene Noci (Age 46)
    Chief Development Officer
  • Mr. Henry Pelish Ph.D.
    Senior Vice President of Drug Discovery
  • Mr. John Soglia Ph.D.
    Senior Vice President of Translational Development














NUVL Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvalent stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NUVL shares.
View NUVL analyst ratings
or view top-rated stocks.

What is Nuvalent's stock price target for 2024?

8 Wall Street analysts have issued twelve-month price objectives for Nuvalent's shares. Their NUVL share price targets range from $42.00 to $79.00. On average, they expect the company's stock price to reach $60.86 in the next year. This suggests that the stock has a possible downside of 9.4%.
View analysts price targets for NUVL
or view top-rated stocks among Wall Street analysts.

How have NUVL shares performed in 2023?

Nuvalent's stock was trading at $29.78 at the beginning of 2023. Since then, NUVL stock has increased by 125.5% and is now trading at $67.16.
View the best growth stocks for 2023 here
.

When is Nuvalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our NUVL earnings forecast
.

How were Nuvalent's earnings last quarter?

Nuvalent, Inc. (NASDAQ:NUVL) issued its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.01.

What ETFs hold Nuvalent's stock?

ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS).

When did Nuvalent IPO?

(NUVL) raised $151 million in an initial public offering on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share.

Who are Nuvalent's major shareholders?

Nuvalent's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (13.36%), Wellington Management Group LLP (2.73%), Northern Trust Corp (0.43%), Ameriprise Financial Inc. (0.37%), Victory Capital Management Inc. (0.37%) and Invesco Ltd. (0.37%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair.
View institutional ownership trends
.

How do I buy shares of Nuvalent?

Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NUVL) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -